The technology will be introduced to the market using two different strategies. One is to enable the pharmaceutical industry to utilize our technology via license. This strategy will initially be targeted to pharmaceutical companies working with CAR-T. The other strategy is to self-manage our distributions through licenses to GMP-certified labs worldwide. These labs will subsequently provide hospitals and cancer patients with Cromo-T.
We believe these two strategies align well with the vision of decentralizing the Cromo-T cell therapy and making the technology available worldwide.